Research progress of targeted therapeutic drugs for acute myeloid leu-kemia
Acute myeloid leukemia(AML)is the most invasive adult leukemia,and a large number of preclinical and clinical studies have pushed the Food and Drug Administration to gradually approve several targeted drugs suitable for AML.However,the prognosis remains poor in most patients and disease often recurs due to drug resistant mutant cloning.Therefore,it is still necessary to explore new targeted drugs or propose innovative and more reasonable drug use schemes in clinic.This article reviews the progress of clinical research on B-cell lymphoma-2 inhibitors,isocitrate dehydrogenase inhibitors,FMS-like tyrosine kinase inhibitors,and TP53 inhibitors,and briefly describes the role and role of these drugs in the treatment of AML in order to provide ideas for the precision and individualization of future treatment plans.
NETL
NSTL
万方数据
